KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cme (CME) EBITDA (2016 - 2025)

Cme (CME) has disclosed EBITDA for 17 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 7.65% to $1.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.3 billion, a 7.27% increase, with the full-year FY2025 number at $4.2 billion, up 7.58% from a year prior.
  • EBITDA was $1.0 billion for Q4 2025 at Cme, up from $999.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $1.2 billion in Q2 2025 to a low of $631.7 million in Q4 2021.
  • A 5-year average of $886.7 million and a median of $881.8 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: dropped 23.36% in 2021, then increased 29.16% in 2023.
  • Cme's EBITDA stood at $631.7 million in 2021, then increased by 5.79% to $668.3 million in 2022, then increased by 29.16% to $863.2 million in 2023, then grew by 9.72% to $947.1 million in 2024, then increased by 7.65% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for CME's EBITDA are $1.0 billion (Q4 2025), $999.0 million (Q3 2025), and $1.2 billion (Q2 2025).